Clinical Commander

Back to dossier
cardio.dvt.cancer-screening-incidental.v1PRODUCTION
cardio.dvt.cancer-screening-incidental.v1

Incidental DVT on cancer-staging imaging

cardiologyacuteadult
Hard-required inputs
0 / 8
Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Incidental cancer-associated DVT — discovered on staging or surveillance imaging in asymptomatic limb. Treat the same as symptomatic cancer-DVT per ACCP 2021 + ITAC 2022; confirm with US for proximal lesions; rule out anatomic compression (May-Thurner, paraspinal mass, IVC tumor thrombus) and concurrent occult PE

Inputs
1
Actions
0
Advance rule
Set
Advance when

incidental DVT confirmed + anatomic context understood

Patient inputs (9)

Older patients higher cancer-VTE recurrence and bleed risk

Active chemotherapy / immunotherapy / radiation modifies bleed risk + drug interactions; remission status informs eventual AC discontinuation

Confirm DVT location and burden (proximal vs distal) when initial finding was on CT and limb is asymptomatic; informs surveillance-only vs treat decision per ACCP 2021

Baseline platelet count; chemotherapy-induced thrombocytopenia modifies AC dosing or contraindicates AC if severe

Mucosal bleed history (especially GI/GU cancers) shifts choice from DOAC to LMWH

Cancer type drives DOAC vs LMWH choice; luminal GI / intracranial / GU favor LMWH; staging informs prognosis + AC duration shared decision

PICC or port presence drives the catheter-associated UEDVT pathway — keep catheter if functional + ongoing access need; AC for catheter duration plus minimum 3 mo

eGFR for DOAC dosing; cancer patients often have CKD or AKI from chemotherapy or contrast

CT-PA when DVT discovered alongside pulmonary nodules or unexplained dyspnea — rule out concurrent occult PE in same encounter (high rate in cancer)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (4)

4 need judgement
  • informationalsevereivc_tumor_thrombus_with_bland_dvt
    IVC tumor thrombus extension (renal cell, HCC, adrenal cortical carcinoma) discovered with associated bland-thrombus DVT below the lesion
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveremajor_bleed_on_AC_during_chemotherapy_in_incidental_cancer_dvt
    Major bleeding (especially GI / GU mucosal sites) during chemotherapy in patient anticoagulated for incidental cancer-DVT
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatecatheter_associated_upper_extremity_dvt_with_functional_catheter
    Incidental UEDVT discovered alongside functional PICC or port — keep catheter if ongoing chemotherapy access need; AC for catheter retention duration plus minimum 3 months total
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatepersistent_cancer_active_vs_in_remission_AC_duration_decision
    6-month AC landmark in patient with incidental cancer-DVT — decision point on continuation of AC vs discontinuation depends on cancer activity status (active vs in remission ≥1 yr)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

ENTRYoptionalDrives risk stratification
Loading…

Recommended regimen

Incidental cancer-associated DVT — same therapeutic AC as symptomatic; DOAC vs LMWH per cancer type (ACCP 2021 + ITAC 2022)
axis: incidental_cancer_associated_dvt_phenotype
Selected axis "Incidental cancer-associated DVT — same therapeutic AC as symptomatic; DOAC vs LMWH per cancer type (ACCP 2021 + ITAC 2022)" by default fallback (first axis)
  • apixaban
    first line
    doac_factor_xa_direct
    10 mg BID × 7 d → 5 mg BID • PO • BID × 6 months minimum (extend per API-CAT for active cancer)
    triggers: cat_non_mucosal_cancer, no_active_bleed, no_brain_mets, egfr_above_25
    CARAVAGGIO (Agnelli NEJM 2020 PMID 32223112) — apixaban non-inferior to dalteparin LMWH with similar major bleed in non-mucosal cancer; ACCP 2021 + ITAC 2022 first-line for incidental as for symptomatic CAT
    rxcui 1364430
  • edoxaban
    first line
    doac_factor_xa_direct
    60 mg daily after 5 d LMWH lead-in (30 mg if CrCl 15-50 or weight ≤60 kg) • PO • daily × 6 months minimum
    triggers: cat_non_mucosal_cancer, lmwh_lead_in_completed, egfr_above_15
    Hokusai-Cancer (Raskob NEJM 2018 PMID 29231094) — edoxaban non-inferior; higher GI bleed in luminal GI subgroup
    rxcui 1599538
  • rivaroxaban
    comorbidity specific
    doac_factor_xa_direct
    15 mg BID × 21 d → 20 mg daily • PO • BID then daily × 6 months
    triggers: cat_non_mucosal_cancer, no_GI_or_GU_cancer, egfr_above_30
    SELECT-D (Young JCO 2018 PMID 29746227) — rivaroxaban reduces recurrent VTE vs dalteparin but increases CRNMB; AVOID in GI/GU cancer per subgroup
    rxcui 1114195
  • dalteparin
    first line
    lmwh
    200 IU/kg SC daily × 1 month → 150 IU/kg SC daily • SC • daily × 6 months
    triggers: cat_luminal_gi_cancer, cat_intracranial_malignancy, cat_genitourinary_cancer, doac_contraindicated, severe_thrombocytopenia_managed
    CLOT (Lee NEJM 2003 PMID 12853587) — landmark establishing LMWH > VKA in cancer-VTE; remains first-line in mucosal cancers per ITAC 2022
    rxcui 67109
  • enoxaparin
    first line
    lmwh
    1 mg/kg SC BID; reduce to 1 mg/kg daily if CrCl <30 • SC • BID
    triggers: cat_luminal_gi_cancer, pregnancy_with_cancer, doac_drug_interaction
    ASH 2018 in pregnancy; reasonable LMWH alternative to dalteparin
    rxcui 67108

outpatient playbook — drug actions (1)

  1. 1. continue apixaban while cancer active
    rxcui 1364430
    apixaban 5 mg BID (or 2.5 mg BID per API-CAT 2024) • PO • BID
    trigger: Active cancer ongoing
    ITAC 2022; API-CAT PMID 38780119

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Incidental DVT noted on CT chest/abdomen/pelvis ordered for cancer staging or restaging — patient asymptomatic in the involved limb; Incidental DVT on surveillance MRI for known malignancy; Catheter-associated upper-extremity DVT noted on chest CT in patient with PICC or port for active chemotherapy.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Incidental DVT on cancer-staging imaging** (cardio.dvt.cancer-screening-incidental.v1).
Scope: Incidental cancer-associated DVT — discovered on staging or surveillance imaging in asymptomatic limb. Treat the same as symptomatic cancer-DVT per ACCP 2021 + ITAC 2022; confirm with US for proximal lesions; rule out anatomic compression (May-Thurner, paraspinal mass, IVC tumor thrombus) and concurrent occult PE

No severity triggers fired against current inputs.

Plan

Regimen axis: **Incidental cancer-associated DVT — same therapeutic AC as symptomatic; DOAC vs LMWH per cancer type (ACCP 2021 + ITAC 2022)**.
1. apixaban 10 mg BID × 7 d → 5 mg BID PO BID × 6 months minimum (extend per API-CAT for active cancer) (doac_factor_xa_direct, first line) — CARAVAGGIO (Agnelli NEJM 2020 PMID 32223112) — apixaban non-inferior to dalteparin LMWH with similar major bleed in non-mucosal cancer; ACCP 2021 + ITAC 2022 first-line for incidental as for symptomatic CAT
2. edoxaban 60 mg daily after 5 d LMWH lead-in (30 mg if CrCl 15-50 or weight ≤60 kg) PO daily × 6 months minimum (doac_factor_xa_direct, first line) — Hokusai-Cancer (Raskob NEJM 2018 PMID 29231094) — edoxaban non-inferior; higher GI bleed in luminal GI subgroup
3. rivaroxaban 15 mg BID × 21 d → 20 mg daily PO BID then daily × 6 months (doac_factor_xa_direct, comorbidity specific) — SELECT-D (Young JCO 2018 PMID 29746227) — rivaroxaban reduces recurrent VTE vs dalteparin but increases CRNMB; AVOID in GI/GU cancer per subgroup
4. dalteparin 200 IU/kg SC daily × 1 month → 150 IU/kg SC daily SC daily × 6 months (lmwh, first line) — CLOT (Lee NEJM 2003 PMID 12853587) — landmark establishing LMWH > VKA in cancer-VTE; remains first-line in mucosal cancers per ITAC 2022
5. enoxaparin 1 mg/kg SC BID; reduce to 1 mg/kg daily if CrCl <30 SC BID (lmwh, first line) — ASH 2018 in pregnancy; reasonable LMWH alternative to dalteparin

Setting playbook (outpatient) — Long-term incidental cancer-DVT survivors: ongoing AC while cancer active; surveillance for recurrence; transition to no-AC if cancer in durable remission ≥1 year
6. continue apixaban while cancer active apixaban 5 mg BID (or 2.5 mg BID per API-CAT 2024) PO BID — Active cancer ongoing (ITAC 2022; API-CAT PMID 38780119)

Non-pharmacologic actions:
- Lifestyle counseling (nutrition, mobility, weight)
- Vaccination per immunocompromised guidelines
- Khorana score for VTE risk in future chemotherapy cycles

AVOID / contraindication checks:
- Doac_avoid_active_mucosal_bleed (CARAVAGGIO subgroup)
- Doac_avoid_brain_mets_or_intracranial_malignancy (intracranial bleed risk)
- Edoxaban_caution_in_luminal_gi_cancer_higher_bleed (Hokusai Cancer subgroup)
- Rivaroxaban_avoid_gi_or_gu_cancer (SELECT D subgroup)
- Apixaban_egfr_below_15 (FDA label)
- Hold_AC_if_platelet_below_25 (ASH 2021 cancer VTE)
- Decision:incidental_cancer_dvt_treated_same_as_symptomatic (ACCP 2021)
- Decision:keep_catheter_for_ueDVT_if_functional_and_ongoing_access_need (ITAC 2022)
- Decision:duration_indefinite_while_cancer_active (ITAC 2022)

Monitoring

Regimen monitoring:
- cbc weekly during active chemotherapy (ASH 2021)
- creatinine q1mo for doac dose adjustment (FDA labels)
- lfts monthly (chemotherapy + AC interaction)
- cancer imaging q3mo for status reassessment (impacts AC duration)
- bleeding screen at each visit with focus on mucosal sites
- drug interaction review at each chemotherapy change
- limb surveillance us at 3mo for catheter associated uedvt thrombus resolution

Setting (outpatient) monitoring:
- Quarterly visits, CBC + BMP, recurrent VTE symptom review

Follow-up plan: 6-month landmark: continue AC if cancer active per ITAC 2022 (indefinite while active); API-CAT 2024 extended apixaban (months 7–18) reasonable per PMID 38780119; reassess at 12 mo + ongoing per cancer status; stop only when cancer in durable remission ≥1 yr AND minimum 6 mo AC complete; for catheter-associated UEDVT — continue AC for catheter retention duration plus minimum 3 mo
- Close-out criterion: extended-AC plan documented

Monitoring phase: CBC weekly during chemotherapy; LFTs monthly; reassess cancer status every 3 mo; bleeding screen at each visit (mucosal sites); drug interaction review at each chemotherapy change; surveillance imaging at 3 mo for thrombus resolution if catheter-associated

Disposition

Current setting: outpatient — Long-term incidental cancer-DVT survivors: ongoing AC while cancer active; surveillance for recurrence; transition to no-AC if cancer in durable remission ≥1 year

Disposition criteria:
- Indefinite AC while cancer active; stop only with durable remission

Escalation triggers (move to higher acuity):
- Cancer recurrence after remission → resume full AC
- New cancer in survivor → re-evaluate AC strategy

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [SEVERE] IVC tumor thrombus extension (renal cell, HCC, adrenal cortical carcinoma) discovered with associated bland-thrombus DVT below the lesion
- [SEVERE] Major bleeding (especially GI / GU mucosal sites) during chemotherapy in patient anticoagulated for incidental cancer-DVT
- [MODERATE] Incidental UEDVT discovered alongside functional PICC or port — keep catheter if ongoing chemotherapy access need; AC for catheter retention duration plus minimum 3 months total

Citations

- ACCP/CHEST 2021 + ITAC-CME 2022 + ASH 2021 Cancer-VTE [PMID:34352295](https://pubmed.ncbi.nlm.nih.gov/34352295/)
- Cited evidence (PMID 35727697) [PMID:35727697](https://pubmed.ncbi.nlm.nih.gov/35727697/)
- Cited evidence (PMID 33007077) [PMID:33007077](https://pubmed.ncbi.nlm.nih.gov/33007077/)
- Cited evidence (PMID 12853587) [PMID:12853587](https://pubmed.ncbi.nlm.nih.gov/12853587/)
- Cited evidence (PMID 32223112) [PMID:32223112](https://pubmed.ncbi.nlm.nih.gov/32223112/)

Last reconciled with current guidelines: 2026-05-15.
References